MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.27701

Медицинская библиотека · American journal of hematology · 2025

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

Chalandon Yves, Devillier Raynier, Boumendil Ariane, Nguyen Stephanie, Bulabois Claude-Eric, Ceballos Patrice, Brissot Eolia, Rubio Marie-Thérèse, Labussière-Wallet Hélène, Maertens Johan, Chevallier Patrice, Maillard Natacha, Poiré Xavier, Castilla-Llorente Cristina, Beguin Yves, Cornillon Jérôme, Maury Sébastien, Marchand Tony, Daguindau Etienne, Bay Jacques-Olivier, Turlure Pascal, Joris Magalie, Menard Anne-Lise, Bilger Karin, Guillerm Gaelle, François Sylvie, Bazarbachi Ali, Chantepie Sylvain, Lewalle Philippe, Marçais Ambroise, Loschi Michael, Benakli Malek, Chauvet Paul, Forcade Edouard, Huynh Anne, Robin Marie, Masouridi-Levrat Stavroula

СтатьяПеревод пока не подготовлен

Аннотация

There are very limited data regarding the outcomes of elderly patients with acute lymphoblastic leukemia (ALL) who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 316 ALL patients aged ≥ 60 years who underwent alloHSCT between 2010 to 2022 were identified in the SFGM-TC registry. The primary objective was to evaluate progression-free survival (PFS), non-relapse mortality (NRM), relapse incidence (RI), and graft-versus-host disease (GvHD)-free relapse-free survival (GRFS), as well as their risk factors. The median age was 63.8 years (range 60-75.8), 49.8% of patients had Philadelphia-positive B-ALL (Ph + ALL), and 70.9% were in first complete remission (CR1) at transplantation. The donor was an unrelated donor in 52.1%, a matched related donor (MRD) in 26.3%, and a haplo-identical donor in 17.7%. Reduced-intensity conditioning (RIC) was administered to 64.6% of patients, while total body irradiation (TBI) was used in 35.8%. The 3-year overall survival (OS) was 46% (95% CI 40%-53%). The 3-year PFS, NRM, RI, and GRFS were 41% (95% CI 35%-48%), 23% (95% CI 18%-28%), 36% (95% CI 31%-42%), and 30% (95% CI 25%-37%), respectively. Multivariable analyses confirmed poorer OS and PFS in patients with advanced disease, with an HR of 1.79 (95% CI 1.22-2.64), p = 0.0032. Additionally, the ALL subtype significantly impacted outcomes, with an HR of 1.99 (95% CI 1.42-2.79) for non-Ph + ALL. This study suggests that alloHSCT is a viable option for elderly ALL patients, as age itself did not impact outcomes. However, advanced disease and non-Ph + ALL were associated with significantly worse survival.

Для цитирования: Chalandon Yves, Devillier Raynier, Boumendil Ariane, Nguyen Stephanie, Bulabois Claude-Eric, Ceballos Patrice, Brissot Eolia, Rubio Marie-Thérèse, Labussière-Wallet Hélène, Maertens Johan, Chevallier Patrice, Maillard Natacha, Poiré Xavier, Castilla-Llorente Cristina, Beguin Yves, Cornillon Jérôme, Maury Sébastien, Marchand Tony, Daguindau Etienne, Bay Jacques-Olivier, Turlure Pascal, Joris Magalie, Menard Anne-Lise, Bilger Karin, Guillerm Gaelle, François Sylvie, Bazarbachi Ali, Chantepie Sylvain, Lewalle Philippe, Marçais Ambroise, Loschi Michael, Benakli Malek, Chauvet Paul, Forcade Edouard, Huynh Anne, Robin Marie, Masouridi-Levrat Stavroula. Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).. American journal of hematology. 2025. DOI: 10.1002/ajh.27701.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.